[23,25,26] The pivotal role of MDM2 and MDM4 in the control of p53 function argues that polymorphisms at these loci should be scrutinized for potential modulation of p53 function. The range of ...

p53 lies at the hub of a vast signalling network. Polymorphisms in upstream activators, repressors or downstream effectors of p53 might individually modulate cancer risk or interact with ...

FMC-220 is a first-in-class covalent activator of p53Y220Cdesigned to address potency and tolerability challenges of non-covalent approachesIn ...

This innovative drug candidate leverages a covalent design to deliver prolonged target engagement, driving durable activation of p53 function inducing tumor cell senescence and importantly, ...

Dgkζ‐Tg mice showed lower p53 protein expression levels, preserved cardiac function, and improved survival rates compared with wild‐type littermates after doxorubicin administration. RNA sequence ...

Frontier Medicines Corp. has announced the selection of FMC-220, a first-in-class covalent small-molecule activator of p53 Y220C designed to address potency and tolerability challenges of noncovalent ...

Mechanistically, NOLC1 binds to the p53 DNA binding domain (DBD), decreasing p53 nuclear translocation stimulated by Cis and suppressing p53 transcriptional functions. Then, the p53-mediated ...